Skip navigation

New partnership to develop advanced pan-fungal diagnostic assay

21 January 2009

Renishaw Diagnostics (previously D3 Technologies Ltd), a world leading provider of novel detection technologies, and the research team in the Department of Medical Microbiology, School of Medicine Cardiff University, in association with the National Public Health Service for Wales, have signed an agreement to develop an advanced multiplex pan-fungal diagnostic assay.

Traditional laboratory tests can take up to 48 hours to provide a diagnostic result, during which time the patient may be at high risk. The ability to give clinicians a clear indication of the presence or absence of infection within 8 hours is expected to markedly improve treatment success. Moreover, the aim to identify the fungal type at speciate level will allow a more tailored therapeutic regimen to be employed.

A pan-European clinical evaluation of the assay is planned to commence in December 2009.


About Renishaw Diagnostics Ltd

Renishaw Diagnostics Ltd, formerly D3 Technologies Ltd, was a Strathclyde University spin-out before being acquired by the Renishaw Group, which is a leading global supplier of engineering technologies, medical devices and Raman spectroscopy systems. It is focused on developing and commercialising its first in vitro diagnostic (IVD) and clinical research products, with the goal of establishing Renishaw Diagnostics as the premium provider of automated, multiplex, high sensitivity molecular diagnostics products for the detection of human infectious diseases.

Enquiries: Caterina Netti, Head of Operations and Technology (+44 141 5577900)